Erste Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-307,769
| Closed | -$11.8M | – | 594 |
|
|
2023
Q2 | $11.8M | Hold |
307,769
| – | – | 0.21% | 124 |
|
|
2023
Q1 | $7.12M | Hold |
307,769
| – | – | 0.14% | 171 |
|
|
2022
Q4 | $8.06M | Hold |
307,769
| – | – | 0.17% | 151 |
|
|
2022
Q3 | $6.05M | Sell |
307,769
-15,000
| -5% | -$301K | 0.14% | 179 |
|
|
2022
Q2 | $5.65M | Sell |
322,769
-23,500
| -7% | -$369K | 0.13% | 188 |
|
|
2022
Q1 | $5.66M | Buy |
346,269
+40,000
| +13% | +$544K | 0.11% | 204 |
|
|
2021
Q4 | $4.94M | Buy |
306,269
+45,000
| +17% | +$641K | 0.09% | 205 |
|
|
2021
Q3 | $3.33M | Buy |
261,269
+30,000
| +13% | +$395K | 0.07% | 244 |
|
|
2021
Q2 | $3.27M | Buy |
231,269
+25,000
| +12% | +$400K | 0.07% | 250 |
|
|
2021
Q1 | $3.21M | Buy |
206,269
+15,600
| +8% | +$254K | 0.08% | 223 |
|
|
2020
Q4 | $3.1M | Sell |
190,669
-16,001
| -8% | -$241K | 0.09% | 215 |
|
|
2020
Q3 | $2.5M | Buy |
206,670
+12,000
| +6% | +$161K | 0.09% | 219 |
|
|
2020
Q2 | $2.24M | Sell |
194,670
-35,000
| -15% | -$483K | 0.09% | 217 |
|
|
2020
Q1 | $3.12M | Sell |
229,670
-57,000
| -20% | -$674K | 0.18% | 140 |
|
|
2019
Q4 | $1.71M | Buy |
286,670
+28,000
| +11% | +$152K | 0.08% | 225 |
|
|
2019
Q3 | $1.37M | Buy |
258,670
+38,800
| +18% | +$258K | 0.07% | 224 |
|
|
2019
Q2 | $1.72M | Buy |
219,870
+36,000
| +20% | +$548K | 0.09% | 193 |
|
|
2019
Q1 | $3.64M | Buy |
183,870
+98,870
| +116% | +$1.72M | 0.2% | 122 |
|
|
2018
Q4 | $1.12M | Buy |
+85,000
| New | +$1.7M | 0.08% | 223 |
|
Erste Asset Management's KDNY Position: Q3 2023 in Review
Erste Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 307,769 shares — an estimated $11.8M sold.
Erste Asset Management first reported a position in KDNY in Q4 2018 and held it in 19 quarters. The position peaked at $11.8M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Erste Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Erste Asset Management sold 307,769 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $11.8M.
- Erste Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2018 and held it in 19 quarters.
- Erste Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $11.8M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Erste Asset Management's 13F filing for Q3 2023, filed 26 Nov 2024.